Last Price
0.09
Today's Change
-0.01 (10.00%)
Day's Change
0.087 - 0.104
Trading Volume
21,491,684
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Zeeshan Saeed Mr. Zeeshan Saeed
Full Time Employees: 17 17
IPO Date: 2018-06-08 2018-06-08
CIK: 0001771885 0001771885
ISIN: CA35954B4047 CA35954B4047
CUSIP: 35954B206 35954B206
Beta: 0.85 0.85
Last Dividend: 0.00 0.00
Dcf Diff: 0.05 0.05
Dcf: 0.04 0.04
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.